Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Johnson and Johnson
Fish and Richardson
Covington
McKesson
Cantor Fitzgerald
US Department of Justice
Mallinckrodt
Deloitte
Medtronic

Generated: October 23, 2017

DrugPatentWatch Database Preview

CANCIDAS Drug Profile

« Back to Dashboard

What is the patent landscape for Cancidas, and when can generic versions of Cancidas launch?

Cancidas is a drug marketed by Merck and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-one patent family members in forty countries and five supplementary protection certificates in five countries.

The generic ingredient in CANCIDAS is caspofungin acetate. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.

Summary for Tradename: CANCIDAS

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list21
Clinical Trials: see list15
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:CANCIDAS at DailyMed

Pharmacology for Tradename: CANCIDAS

Ingredient-typeLipopeptides
Drug ClassEchinocandin Antifungal
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
CANCIDAS
caspofungin acetate
POWDER;IV (INFUSION)021227-001Jan 26, 2001APRXYesYes► Subscribe► SubscribeY► Subscribe
Merck
CANCIDAS
caspofungin acetate
POWDER;IV (INFUSION)021227-002Jan 26, 2001APRXYesYes► Subscribe► SubscribeY► Subscribe
Merck
CANCIDAS
caspofungin acetate
POWDER;IV (INFUSION)021227-001Jan 26, 2001APRXYesYes► Subscribe► SubscribeY► Subscribe
Merck
CANCIDAS
caspofungin acetate
POWDER;IV (INFUSION)021227-002Jan 26, 2001APRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CANCIDAS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck
CANCIDAS
caspofungin acetate
POWDER;IV (INFUSION)021227-001Jan 26, 2001► Subscribe► Subscribe
Merck
CANCIDAS
caspofungin acetate
POWDER;IV (INFUSION)021227-002Jan 26, 2001► Subscribe► Subscribe
Merck
CANCIDAS
caspofungin acetate
POWDER;IV (INFUSION)021227-002Jan 26, 2001► Subscribe► Subscribe
Merck
CANCIDAS
caspofungin acetate
POWDER;IV (INFUSION)021227-002Jan 26, 2001► Subscribe► Subscribe
Merck
CANCIDAS
caspofungin acetate
POWDER;IV (INFUSION)021227-001Jan 26, 2001► Subscribe► Subscribe
Merck
CANCIDAS
caspofungin acetate
POWDER;IV (INFUSION)021227-002Jan 26, 2001► Subscribe► Subscribe
Merck
CANCIDAS
caspofungin acetate
POWDER;IV (INFUSION)021227-002Jan 26, 2001► Subscribe► Subscribe
Merck
CANCIDAS
caspofungin acetate
POWDER;IV (INFUSION)021227-001Jan 26, 2001► Subscribe► Subscribe
Merck
CANCIDAS
caspofungin acetate
POWDER;IV (INFUSION)021227-001Jan 26, 2001► Subscribe► Subscribe
Merck
CANCIDAS
caspofungin acetate
POWDER;IV (INFUSION)021227-001Jan 26, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for CANCIDAS

Drugname Dosage Strength RLD Submissiondate
caspofungin acetateFor Injection50 mg/vial and 70 mg/vialCancidas6/26/2009

International Patent Family for Tradename: CANCIDAS

Country Document Number Estimated Expiration
Eurasian Patent Organization001386► Subscribe
Hungary9901586► Subscribe
Portugal904098► Subscribe
Slovakia144898► Subscribe
Algeria2205► Subscribe
Australia706250► Subscribe
Czech Republic289361► Subscribe
Israel126479► Subscribe
China1222082► Subscribe
Germany69722615► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CANCIDAS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2001Austria► SubscribePRODUCT NAME: CASPOFUNGIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE CASPOFUNGINACETAT; REGISTRATION NO/DATE: EU/01/196/001-003 20011024
C0054France► SubscribePRODUCT NAME: CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001 20011024
C/GB02/002United Kingdom► SubscribeA SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016.
00076Netherlands► SubscribePRODUCT NAME: CASPOFUNGINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER CASPOFUNGINE ACETAAT; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024
01/029Ireland► SubscribePRODUCT NAME: CASPOFUNGIN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024; PAEDIATRIC INV. PLAN: P/30/2008
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Chinese Patent Office
Johnson and Johnson
Moodys
Daiichi Sankyo
US Department of Justice
Deloitte
Cerilliant
Julphar
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot